David Westenberg
Stock Analyst at Piper Sandler
(3.86)
# 715
Out of 4,761 analysts
153
Total ratings
46.15%
Success rate
11.39%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Reiterates: Neutral | $2.5 → $2 | $1.54 | +29.87% | 7 | Feb 20, 2025 | |
| ADPT Adaptive Biotechnologies | Reiterates: Overweight | $7 → $11 | $8.27 | +33.01% | 12 | Feb 20, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $240 → $260 | $249.85 | +4.06% | 3 | Feb 10, 2025 | |
| ILMN Illumina | Maintains: Overweight | $185 → $190 | $94.20 | +101.70% | 15 | Feb 10, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $210 → $200 | $160.46 | +24.64% | 12 | Feb 10, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $435 → $510 | $452.77 | +12.64% | 10 | Feb 10, 2025 | |
| DGX Quest Diagnostics | Reiterates: Neutral | $165 → $180 | $172.24 | +4.51% | 6 | Feb 3, 2025 | |
| NEOG Neogen | Reiterates: Neutral | $17 → $13 | $10.04 | +29.48% | 10 | Jan 21, 2025 | |
| AKYA Akoya Biosciences | Reiterates: Overweight | $4 → $3 | $2.05 | +46.34% | 7 | Nov 19, 2024 | |
| NTRA Natera | Maintains: Overweight | $150 → $200 | $162.31 | +23.22% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $40 → $70 | $68.09 | +2.81% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $16.46 | +33.66% | 6 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $75 | $49.26 | +52.25% | 9 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $8.5 | $5.12 | +66.02% | 8 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $34 | $42.87 | -20.69% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $11.02 | +45.19% | 8 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $11.10 | +80.18% | 7 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.65 | +13.21% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $10.90 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $40.46 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $32.95 | - | 1 | Nov 21, 2017 |
Pacific Biosciences of California
Feb 20, 2025
Reiterates: Neutral
Price Target: $2.5 → $2
Current: $1.54
Upside: +29.87%
Adaptive Biotechnologies
Feb 20, 2025
Reiterates: Overweight
Price Target: $7 → $11
Current: $8.27
Upside: +33.01%
Labcorp Holdings
Feb 10, 2025
Maintains: Neutral
Price Target: $240 → $260
Current: $249.85
Upside: +4.06%
Illumina
Feb 10, 2025
Maintains: Overweight
Price Target: $185 → $190
Current: $94.20
Upside: +101.70%
Zoetis
Feb 10, 2025
Maintains: Overweight
Price Target: $210 → $200
Current: $160.46
Upside: +24.64%
IDEXX Laboratories
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $452.77
Upside: +12.64%
Quest Diagnostics
Feb 3, 2025
Reiterates: Neutral
Price Target: $165 → $180
Current: $172.24
Upside: +4.51%
Neogen
Jan 21, 2025
Reiterates: Neutral
Price Target: $17 → $13
Current: $10.04
Upside: +29.48%
Akoya Biosciences
Nov 19, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $2.05
Upside: +46.34%
Natera
Nov 18, 2024
Maintains: Overweight
Price Target: $150 → $200
Current: $162.31
Upside: +23.22%
Nov 12, 2024
Reiterates: Neutral
Price Target: $40 → $70
Current: $68.09
Upside: +2.81%
Nov 11, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $16.46
Upside: +33.66%
Nov 11, 2024
Maintains: Overweight
Price Target: $85 → $75
Current: $49.26
Upside: +52.25%
Nov 11, 2024
Maintains: Overweight
Price Target: $8 → $8.5
Current: $5.12
Upside: +66.02%
Aug 13, 2024
Maintains: Overweight
Price Target: $30 → $34
Current: $42.87
Upside: -20.69%
Jul 1, 2024
Maintains: Neutral
Price Target: $19 → $16
Current: $11.02
Upside: +45.19%
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $11.10
Upside: +80.18%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.65
Upside: +13.21%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $10.90
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $40.46
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $32.95
Upside: -